Medical Device and Healthcare Industry Trends (의료기기 및 헬스케어 산업 동향)
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Lunit is gaining serious traction in the North American market, hitting over 330 sites in the U.S. while snagging a new FDA approval for its 3D breast imaging AI. Meanwhile, in the U.S., the CMS and FDA are teaming up to propose a fast-track reimbursement path for breakthrough devices. Back home, there's a brewing debate over whether to split manufacturing licenses from product approvals, which is definitely something to keep an eye on.
Medical Device and Healthcare Industry Trends — April 25, 2026
Top 5 Headlines Today
- Lunit: Surpasses 330 breast imaging AI installations in the U.S.; secures additional FDA approval for its updated 3D mammography AI tool.
- CMS & FDA: Jointly propose a new fast-track Medicare reimbursement pathway for FDA-designated "breakthrough" devices to drastically cut the time between approval and coverage.
- Hit News: Intense debate ignites over separating medical device manufacturing permits from product marketing approvals, with calls to reform the regulatory system for outsourced production.
- GiVita: Digital healthcare startup secures 4.5 billion KRW in Series A funding, with plans to expand digital services for pre-diabetic patients.
- FDA: Rejects a proposal to deregulate certain AI medical devices, upholding strict oversight requirements for AI tech.
Key Corporate Updates (4 Cases)
Lunit — 330+ U.S. Sites and New 3D FDA Approval
- What happened: Lunit announced that its AI for breast cancer screening is now used at over 330 sites across the U.S. and Latin America. They also received new FDA approval for their updated 3D breast imaging (digital breast tomosynthesis) AI.
- Key figure: 330+ screening sites in the U.S. and South America.
- Takeaway: Lunit is becoming a gold standard for how to scale AI medical devices globally. The 3D approval is a huge win for their product lineup and revenue diversification.
GiVita — 4.5 Billion KRW Series A Funding
- What happened: Digital healthcare startup GiVita raised 4.5 billion KRW in Series A funding. They plan to use the capital to build digital services for pre-diabetic patients and digitize offline medical protocols.
- Key figure: 4.5 billion KRW Series A investment.
- Takeaway: Investment is pouring into preventive digital health. The real challenge for domestic startups is moving from regulatory approval to a sustainable, scalable business model.
Hit News: Debate on Manufacturing vs. Product Approvals
- What happened: Industry insiders are calling for a split between "manufacturing site permits" and "product approvals." Specifically, there’s confusion regarding how to apply Article 18 of the MFDS notification when major processes are outsourced.
- Takeaway: With outsourcing becoming the industry norm, we urgently need clearer guidelines. How the MFDS interprets these rules will directly impact production flexibility.
U.S. CMS & FDA — Innovation Reimbursement Fast-Track
- What happened: The CMS and FDA are proposing a new path to link FDA breakthrough designation with Medicare reimbursement, aiming to speed up access for patients.
- Takeaway: This aligns with global trends like Korea’s "Immediate Market Access" system. It’s a huge incentive for Korean companies to secure FDA breakthrough status when targeting the U.S.
Policy & Regulation (3 Cases)
Manufacturing vs. Product Approval Debate
- Details: Companies that handle design, packaging, and inspection in-house but outsource major processes are currently stuck in a regulatory gray area under Article 18 of the MFDS guidelines. The industry is pushing for a clear separation of permits to allow better operational flexibility.
End of Grace Period for GMP Violations
- Details: The practice of allowing imports/sales during the grace period for expired GMP certificates is over. Even if a product meets quality standards, failing the GMP audit now leads to an immediate sales halt. This puts extra pressure on IVD (in-vitro diagnostic) companies to keep their quality systems sharp.
Digital Medical Device Classification
- Details: The MFDS regulation (No. 2025-23) on digital medical product classification is now in full swing. It provides concrete criteria for grading AI and big data-based innovations, making it easier for developers to plan their regulatory strategy from day one.
Digital Health & AI Highlights
- Lunit: Building a massive footprint in the U.S. with 330+ sites, proving that steady clinical integration is the key to global market share.
- GiVita: Focusing on the "doctor-patient data ecosystem" for pre-diabetics.
- Industry Sentiment: Many say that even with great tech, the lack of reimbursement remains a major hurdle. Companies are looking at U.S. (CMS remote monitoring) and UK (NICE) models as benchmarks.
Today's Insight
Lunit's success highlights the gap between Korea’s robust regulatory approval process and the struggle to achieve "clinical integration" at home. While the U.S. (CMS/FDA) is moving to make reimbursement faster for innovators, Korea needs to pick up the pace to ensure our startups don't hit a wall after they receive their approvals.
Weekly Checkpoints
- Watch: Any legislative drafts regarding the separation of manufacturing and product licenses by the MFDS.
- Check: Lunit’s Q1 2026 performance and any further updates on their U.S. operations.
- Review: Official rule-making schedules and comment periods for the new U.S. CMS/FDA reimbursement path.
Reader Action Items
- For Practitioners: Review the new GMP grace period rules with your quality team and double-check your audit schedule.
- For Investors: Compare Lunit’s expansion speed with its AI competitors to re-evaluate valuations.
- For Founders: Research how global peers handle reimbursement so you can build a solid cross-border business strategy from the start.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
